Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (review)

Oncology Letters

Volumn 4, Issue 6, 2012, Pages 1151-1157

  Zheng, Jie ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancer; Glycolysis; Oxidative phosphorylation

Indexed keywords

GLUTAMINE; MITOCHONDRIAL DNA;

CANCER CELL; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; MICROENVIRONMENT; NEOPLASM; ONCOGENE; OXIDATIVE PHOSPHORYLATION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84867249149     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.928     Document Type: Review

References (79)

1. Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337, 2011.
2. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
3. Griguer CE, Oliva CR and Gillespie GY: Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol 74: 123-133, 2005.
4. Fantin VR, St-Pierre J and Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434, 2006.
5. Hsu PP and Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707, 2008.
6. Lim HY, Ho QS, Low J, Choolani M and Wong KP: Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion 11: 437-443, 2011.
7. Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL and Smith JW: Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 286: 42626-42634, 2011.
8. Zu XL and Guppy M: Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313: 459-465, 2004.
9. Brooks GA: Cell-cell and intracellular lactate shuttles. J Physiol 587: 5591-5600, 2009.
10. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA and Raichle ME: Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA 107: 17757-17762, 2010.
11. Pfeiffer T, Schuster S and Bonhoeffer S: Cooperation and competition in the evolution of ATP-producing pathways. Science 292: 504-507, 2001.
12. Miccheli A, Tomassini A, Puccetti C, Valerio M, Peluso G, Tuccillo F, Calvani M, Manetti C and Conti F: Metabolic profiling by 13C-NMR spectroscopy: [1,2-13C2]glucose reveals a heterogeneousmetabolism in human leukemia T cells. Biochimie 88: 437-448, 2006.
13. Berridge MV, Herst PM and Tan AS: Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 10: 584-588, 2010.
14. Chen JL, Lucas JE, Schroeder T, Mori S, Wu J, Nevins J, Dewhirst M, West M and Chi JT: The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet 4: e1000293, 2008.
15. Marusyk A and Polyak K: Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805: 105-117, 2010.
16. Suganuma K, Miwa H, Imai N, Shikami M, Gotou M, Goto M, Mizuno S, Takahashi M, Yamamoto H, Hiramatsu A, et al: Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leuk Lymphoma 51: 2112-2119, 2010.
17. Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells. FEBS J 274: 1393-1418, 2007.
18. Jose C, Bellance N and Rossignol R: Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim Biophys Acta 1807: 552-561, 2011.
19. Smolková K, Plecitá-Hlavatá L, Bellance N, Benard G, Rossignol R and Ježek P: Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 43: 950-968, 2011.
20. Herst PM and Berridge MV: Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochim Biophys Acta 1767: 170-177, 2007.
21. Rodríguez-Enríquez S, Carreño-Fuentes L, Gallardo-Pérez JC, Saavedra E, Quezada H, Vega A, Marín-Hernández A, OlínSandoval V, TorresMárquez ME and MorenoSánchez R: Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. Int J Biochem Cell Biol 42: 1744-1751, 2010.
22. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, et al: Ketones and lactate 'fuel' tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9: 3506-3514, 2010.
23. Pavlides S, WhitakerMenezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F and Lisanti MP: The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984-4001, 2009.
24. Kiaris H, Chatzistamou I, Kalofoutis Ch, Koutselini H, Piperi Ch and Kalofoutis A: Tumour-stroma interactions in carcinogenesis: basic aspects and perspectives. Mol Cell Biochem 261: 117-122, 2004.
25. Koukourakis MI, Giatromanolaki A, Harris AL and Sivridis E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 66: 632-637, 2006.
26. Feron O: Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92: 329-333, 2009.
27. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W and Myers JN: Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117: 2926-2938, 2011.
28. Porporato PE, Dhup S, Dadhich RK, Copetti T and Sonveaux P: Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2: 49, 2011.
29. Bélanger M, Allaman I and Magistretti PJ: Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14: 724-738, 2011.
30. Lunt SY and Vander Heiden MG: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27: 441-464, 2011.
31. Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
32. Gatenby RA and Gillies RJ: A microenvironmental model of carcinogenesis. Nat Rev Cancer 8: 56-61, 2008.
33. Vaupel P: Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 32: 125-127, 2010.
34. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713, 2008.
35. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T and Hay N: Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14: 458-470, 2008.
36. Chandra D and Singh KK: Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta 1807: 620-625, 2011.
37. Owens KM, Kulawiec M, Desouki MM, Vanniarajan A and Singh KK: Impaired OXPHOS complex III in breast cancer. PLoS One 6: e23846, 2011.
38. LópezRíos F, Sánchez-Aragó M, García-García E, Ortega AD, Berrendero JR, Pozo-Rodríguez F, López-Encuentra A, Ballestín C and Cuezva JM: Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 67: 9013-9017, 2007.
39. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB and Thompson CB: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105: 18782-18787, 2008.
40. DeBerardinis RJ and Cheng T: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324, 2010.
41. Reitzer LJ, Wice BM and Kennell D: Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 254: 2669-2676, 1979.
42. Guppy M, Leedman P, Zu X and Russell V: Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 364: 309-315, 2002.
43. Yuneva M, Zamboni N and Oefner P, Sachidanandam R and Lazebnik Y: Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 178: 93-105, 2007.
44. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG and DeBerardinis RJ: Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69: 7986-7993, 2009.
45. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP and Martinez-Outschoorn UE: Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance. Cancer Biol Ther 12: 1085-1097, 2011.
46. Dang CV, Le A and Gao P: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483, 2009.
47. Yuneva M: Finding an 'Achilles' heel' of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle 7: 2083-2089, 2008.
48. Zheng J: Features of energy metabolism and clinical application in cancer growth. Chin J Cell Biol 33: 1158-1165, 2011.
49. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and DeBerardinis RJ: Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481: 385-388, 2012.
50. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL and Thompson CB: The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173, 2005.
51. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899, 2004.
52. Levine AJ and PuzioKuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330: 1340-1344, 2010.
53. Bayley JP and Devilee P: The Warburg effect in 2012. Curr Opin Oncol 24: 62-67, 2012.
54. Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, et al: K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res 22: 399-412, 2012.
55. Majmundar AJ, Wong WJ and Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309, 2010.
56. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183, 2010.
57. Pylayeva-Gupta Y, Grabocka E and BarSagi D: RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774, 2011.
58. Yecies JL and Manning BD: mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89: 221-228, 2011.
59. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC and Thompson CB: The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 21: 1037-1049, 2007.
60. Weljie AM and Jirik FR: Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. Int J Biochem Cell Biol 43: 981-989, 2011.
61. Bertout JA, Patel SA and Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 8: 967-975, 2008.
62. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108: 4129-4134, 2011.
63. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
64. David CJ, Chen M, Assanah M, Canoll P and Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368, 2010.
65. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744, 2011.
66. Bluemlein K, Grüning NM, Feichtinger RG, Lehrach H, Kofler B and Ralser M: No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2: 393-400, 2011.
67. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20, 2008.
68. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765, 2009.
69. Dang CV, Kim JW, Gao P and Yustein J: The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56, 2008.
70. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F and Hwang PM: p53 regulates mitochondrial respiration. Science 312: 1650-1653, 2006.
71. Ma W, Sung HJ, Park JY, Matoba S and Hwang PM: A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr 39: 243-246, 2007.
72. Yeung SJ, Pan J and Lee MH: Roles of p53, MYC and HIF-1 in regulating glycolysis -the seventh hallmark of cancer. Cell Mol Life Sci 65: 3981-3999, 2008.
73. Wang PY, Zhuang J and Hwang PM: p53: exercise capacity and metabolism. Curr Opin Oncol 24: 76-82, 2012.
74. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E and Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120, 2006.
75. Vahsen N, Candé C, Brière JJ, Bénit P, Joza N, Larochette N, Mastroberardino PG, Pequignot MO, Casares N, Lazar V, et al: AIF deficiency compromises oxidative phosphorylation. EMBO J 23: 4679-4689, 2004.
76. Zhou S, Kachhap S and Singh KK: Mitochondrial impairment in p53-deficient human cancer cells. Mutagenesis 18: 287-292, 2003.
77. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G, Valenti M, Eccles S, Rouschop K, Wouters B and Ashcroft M: Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 29: 2243-2253, 2009.
78. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: p53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 107: 6334-6339, 2010.
79. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A and Beach D: Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177-185, 2005.